Wahlstrom Mats 4

What Happened
Mats Wahlstrom, a director of Coherus Oncology (CHRS), received awards on June 5, 2026 totaling 90,000 units: 30,000 restricted stock units (RSUs) and 60,000 derivative awards. Both awards were reported at $0.00 per share at grant. These are awards (compensation) rather than open‑market purchases or sales.

Key Details

• Transaction date: 2026-06-05; Form 4 filed 2026-06-09 (filed on time).
• Awards: 30,000 RSUs (Acquired, reported $0.00) and 60,000 derivative awards (Acquired, reported $0.00).
• Vesting: Per filing footnotes, 100% of the RSUs convert to one share per RSU and vest on the one‑year anniversary of June 3, 2026 (i.e., June 3, 2027) subject to continued service. The 60,000 derivative awards become exercisable/vest 100% on June 3, 2027, subject to continued service.
• Shares owned after the transaction: Not specified in the provided excerpt of the filing.
• Transaction code: A = Award/Grant. No 10b5‑1 plan, tax‑withholding or late‑filing flag indicated in the filing excerpt.

Context

• RSUs are a form of compensation that convert to shares upon vesting; derivative awards here are option‑style or similar equity awards that become exercisable on the stated vesting date.
• Grants at $0 per share are standard for equity compensation and do not represent an open‑market purchase or sale by the insider.
• This filing documents standard director compensation and, on its own, does not indicate buying or selling sentiment.